Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Hepatocellular 21Liver Neoplasms 2Differentiated Thyroid Cancer 2Colorectal Neoplasms 2Cholangiocarcinoma 2Carcinoma 2Stomach Neoplasms 1Solid Tumor 1Recurrence 1Pancreatic Neoplasms 1Nasopharyngeal Carcinoma 1Locally Advanced Thyroid Gland Carcinoma 1Leukemia, Myeloid, Acute 1Hepatocellular Carcinoma with PVTT 1Esophageal Neoplasms 1Digestive System Neoplasms 1Diabetes Mellitus 1Cirrhosis, Familial, with Pulmonary Hypertension 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Carcinoma 1Biliary Tract Adenocarcinoma 1Biliary Malignant Tumors 1Advanced Solid Tumor 1

Interventions

pembrolizumab 14Injections 13Paclitaxel 10Nivolumab 10Docetaxel 9Cisplatin 9Capecitabine 9Bevacizumab 8toripalimab 7senaparib 7Fluorodeoxyglucose F18 7Cyclophosphamide 7tislelizumab 6atezolizumab 6Irinotecan 6Fluorouracil 6Gemcitabine 5fludarabine 4apatinib 4Oxaliplatin 4Leucovorin 4Ipilimumab 4spartalizumab 3pertuzumab 3olaparib 3camrelizumab 3Rifampin 3Radiosurgery 3Midazolam 3Itraconazole 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumor × donafenib × Clear all
NCT06239298 2024-06-14

A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1/2 Recruiting
130 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡